Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Daniel M Girardi, Scot A Niglio, Amir Mortazavi...
https://pubmed.ncbi.nlm.nih.gov/35031545/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
314
Participants Needed
582
Research Sites
N/A
Total Duration
This trial studies patients with rare genitourinary tumors that have spread from their original site to other parts of the body. It evaluates the combination of cabozantinib with two immunotherapy drugs, nivolumab and ipilimumab, to see how well this approach works. The study focuses on patients who have few or no treatment options, aiming to assess response rates and survival outcomes. Participants receive cabozantinib orally daily on specific days during treatment cycles, alongside nivolumab and ipilimumab given intravenously at the start of initial cycles. After four cycles, nivolumab is continued alone every 28 days. Treatment continues for up to two years unless the disease progresses or side effects are unacceptable. Imaging tests like CT, MRI, bone scans, and PETCT scans are performed throughout the study to monitor disease and treatment effects. During the trial, patients undergo various assessments including echocardiography, blood and urine tests, and scans to track tumor response and safety. After completing treatment, participants are followed every two months for up to five years to observe long-term outcomes. The main focus is on objective tumor response, with additional monitoring of survival and side effects over time.
CONDITIONS
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Triplet Regimen | Current Systemic Therapy (Chemotherapy/Immunotherapy) |
|---|---|---|
| What it is | Combination of the oral targeted drug cabozantinib plus intravenous immunotherapies nivolumab and ipilimumab given in cycles in a single‑arm phase II trial | Current systemic therapies typically include platinum‑based chemotherapy or checkpoint inhibitors used off‑label in similar metastatic rare GU tumors |
| Role in trial | Investigational intervention evaluated in all participants as single‑arm regimen | Not included in the trial; represents external care option |
| Primary use | To evaluate objective response rate, progression‑free and overall survival in metastatic rare GU tumors | To control tumor growth and provide survival benefit using established systemic therapy approaches in metastatic GU cancers |
| How it is given or performed | Cabozantinib is taken orally daily; nivolumab and ipilimumab are given intravenously in initial 21‑day cycles, then nivolumab continued in 28‑day cycles | Platinum‑based chemotherapy is given intravenously every 3‑4 weeks; checkpoint inhibitors are given intravenously every 2‑4 weeks depending on agent |
| Evidence status | Phase I data showed promising response rates in rare GU tumors; phase II is ongoing to confirm activity | Evidence for effectiveness in rare non‑urothelial histologies is limited; practice extrapolated from urothelial carcinoma protocols |
| Important risks | High rates of grade 3 or higher adverse events (up to ~80–84 %) observed in phase I/expansion cohorts | Platinum chemotherapy and immunotherapy each have well‑known toxicities including cytopenias, renal/hepatic effects, and immune‑related events |
| Important limitations | Single‑arm design without comparator group; safety and efficacy data from rare histologies may be limited by small cohort sizes | Lack of prospective trial data in rare non‑urothelial GU tumors; effectiveness and tolerability uncertain in these histologies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Includes echocardiography and baseline imaging tests
Duration - Up to 2 years
Participants receive oral cabozantinib daily on specific days and intravenous nivolumab and ipilimumab during the first four cycles, followed by nivolumab alone in later cycles. Treatment continues for up to two years unless disease worsens or side effects occur.
Cycles every 21 days for first 4 cycles, then every 28 days; regular imaging and lab tests throughout
Duration - Up to 5 years
After treatment ends, participants are followed up every two months for up to five years to monitor long-term outcomes and safety.
Follow-up visits every 2 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Daniel M Girardi, Scot A Niglio, Amir Mortazavi...
https://pubmed.ncbi.nlm.nih.gov/35031545/National Cancer Institute (NCI)
Lead Sponsor